Related Experiment Videos
Antithrombotic therapy in atrial fibrillation
1Faculty of Health Sciences, McMaster University, Hamilton, Ont.
Insights
Anticoagulant therapy significantly reduces stroke risk by 68% in nonrheumatic atrial fibrillation patients. Oral anticoagulants are more effective than aspirin for stroke prevention in this population.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Nonrheumatic atrial fibrillation is a significant risk factor for stroke.
- Antithrombotic therapy is crucial for stroke prevention in these patients.
Purpose of the Study:
- To review evidence on antithrombotic therapy for nonrheumatic atrial fibrillation.
- To compare the efficacy of oral anticoagulants versus aspirin.
Main Methods:
- Systematic review of six trials (five primary prevention, one secondary prevention).
- Trials compared antithrombotic therapy against placebo or no treatment.
- Efficacy and safety of acetylsalicylic acid (ASA) were also assessed.
Main Results:
- Warfarin demonstrated a 68% reduction in stroke risk across patient groups.
- Benefit was consistent except in patients with high hemorrhage risk.
- Absolute benefit varied due to differing baseline stroke risks among subgroups.
Conclusions:
- Anticoagulant therapy is recommended for all atrial fibrillation patients.
- Oral anticoagulants offer superior stroke risk reduction compared to ASA in nonrheumatic atrial fibrillation.
Objective:
To review the evidence for antithrombotic therapy in patients with nonrheumatic atrial fibrillation.
Quality Of Evidence:
Five primary prevention trials and one secondary prevention trial compare antithrombotic therapy with placebo or no treatment. Two trials also determine the efficacy and safety of acetylsalicylic acid.
Main Findings:
Warfarin reduces the risk of stroke by 68%. The effect is consistent in all identifiable groups of patients with nonrheumatic atrial fibrillation, except patients at serious risk of hemorrhage. The absolute benefit of anticoagulants varies among patients because of markedly different inherent risk of stroke among patient subgroups.
Conclusions:
Anticoagulant therapy should be considered for all patients with atrial fibrillation. Oral anticoagulant therapy is more effective than ASA in reducing the risk of stroke among patients with nonrheumatic atrial fibrillation.